



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 217 519 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 05.02.92 (51) Int. Cl. 5: C07D 285/12, C07D 417/04,
A61K 31/41

(21) Application number: 86306325.1

(22) Date of filing: 15.08.86

The file contains technical information submitted
after the application was filed and not included in
this specification

(54) 5-membered heterocyclic ring angiotensin converting enzyme inhibitors.

(30) Priority: 31.08.85 GB 8521697
09.10.85 GB 8524932
06.12.85 GB 8530143
22.04.86 GB 8609793
17.05.86 GB 8612060

(43) Date of publication of application:
08.04.87 Bulletin 87/15

(45) Publication of the grant of the patent:
05.02.92 Bulletin 92/06

(84) Designated Contracting States:
AT DE NL SE

(66) References cited:
EP-A- 0 048 159
US-A- 4 254 267
US-A- 4 312 990

(73) Proprietor: FISONS plc
Fison House Princes Street
Ipswich Suffolk IP1 1QH(GB)

(72) Inventor: Brown, Roger Charles
8 Duncan Way, Gorse Covert,
Loughborough, Leicestershire(GB)
Inventor: Robinson, David Hulme
12 Grassholme Drive,
Loughborough, Leicestershire LE11 0NS(GB)
Inventor: Dixon, John
Church Farmhouse, Main Street, Great
Dalby,
Melton Mowbray, Leicestershire(GB)

(74) Representative: Craig, Christopher Bradberry
et al
Fisons plc 12 Derby Road
Loughborough Leicestershire LE11 0BB(GB)

EP 0 217 519 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention relates to new compounds, methods for their preparation and compositions containing them.

5 A wide variety of angiotensin converting enzyme (ACE) inhibitors are known, eg from French Patent Specification No. 2,372,804 and European Patent Specification No. 0012401.

We have now found a group of compounds having advantageous properties, eg as ACE inhibitors. According to the invention we provide compounds of formula I,

10

15



20

in which R₃ is hydrogen, alkyl C 1 to 10, cycloalkyl C3 to 10, SR₁₀, furanyl, phenyl or phenylalkyl C7 to 12, naphthalenyl, the phenyl group optionally being substituted by alkyl C 1 to 6, or alkoxy C 1 to 6,

R₁₀ is alkyl C 1 to 10,

R is hydrogen, alkyl C1 to 10 or alkyl C1 to 6 substituted by NH₂,

25

Z is R₂CH(COOH)NH- or R₁SCH₂-,

R₁ is hydrogen or R₈CO-,

R₂ is alkyl C 1 to 10 or phenylalkyl C7 to 12, and

R₈ is alkyl C 1 to 10 or phenyl

and pharmaceutically acceptable salts, esters and amides thereof.

30

According to the invention we also provide a process for the production of a compound of formula I, or a pharmaceutically acceptable salt, ester or amide thereof, which comprises

a) removal of a protecting group from a compound of formula I in which one or more of the amino or carboxylic acid groups is protected,

b) reaction of a compound of formula II,

35

40



45

or a salt, ester, amide, tautomer, or protected derivative thereof,
in which R₃ is as defined above, with a compound of formula III,

ZCHR₁COX III

50

in which Z and R are as defined above, and X is a good leaving group,

c) conversion of a compound of formula I in which the asymmetric carbon atom of the thiadiazole ring is in the R configuration into a corresponding compound in which that carbon atom is in the S configuration,

d) reaction of a compound of formula II, in which R₃ is as defined above,
with a compound of formula VI,

ZCHR₁COOH VI

in which Z and R are as defined above, or

e) production of a pharmaceutically acceptable salt of a compound of formula I, by treating a compound of formula I, or another salt, an ester or an amide thereof, with a compound containing an available pharmaceutically acceptable ion and capable of converting the compound of formula I or the other salt, ester or amide thereof, to a pharmaceutically acceptable salt of the compound of formula I,

and where desired or necessary deprotecting the resulting compound, or converting a compound of formula I to a pharmaceutically acceptable salt, ester or amide thereof or vice versa.

In process a) the protecting group can be any convenient protecting group conventionally used in

peptide synthesis and may be removed using techniques conventionally used in peptide synthesis. Thus carboxy protecting groups which may be used are alkoxy C 1 to 6, which may be a straight chain or branched alkoxy, eg t-butyloxy; or phenylalkoxy C7 to 12, eg benzyloxy. These groups can be removed by hydrolysis, for example basic hydrolysis, eg using aqueous methanolic sodium hydroxide; or cleavage using, for example, trifluoracetic acid; or by hydrogenation, eg using palladium on charcoal. Amino-protecting groups which may be mentioned include alkyloxycarbonyl C2 to 7, eg t-butyloxycarbonyl or phenylalkyloxycarbonyl C8 to 13, eg benzyloxycarbonyl. We prefer to use starting materials in which the carboxy groups are protected.

In process b) the group X may be halo, eg bromo or chloro. The reaction may be carried out in a solvent which is inert under the reaction conditions, eg acetonitrile, at a temperature of from 0° to 100° C, preferably at about 30° C. The reaction is preferably carried out under basic conditions, eg in the presence of triethylamine or polyvinylpyridine.

The reaction of process c) may be carried out in a solvent which is inert under the reaction conditions, eg acetonitrile, at a temperature of from 0° C to the boiling point of the solvent, preferably of from 20° to 30° C. The reaction may be carried out under anhydrous conditions, eg in the presence of molecular sieves, and in the presence of a base, eg pyrrolidine.

In the reaction of process d) any conventional peptide synthesis methods may be used.

The reaction may comprise the formation of, optionally *in situ*, an activated derivative of an acid, eg an anhydride or dicyclohexylcarbodiimide derivative. The reaction may be carried out in a solvent which is inert under the reaction conditions, eg dichloromethane or ethyl acetate, at a temperature of from -10° C to the boiling point of the solvent, preferably of from 0° C to 30° C. The reaction may be carried out in the presence of a base, eg triethylamine. When the reaction involves dicyclohexylcarbodiimide it may be carried out in the presence of an activating agent, eg hydroxybenzotriazole.


The reaction will of course vary with the particular activated derivative used.

In process e) the salts may be formed by reacting the free acid, or a salt, ester, amide or derivative thereof, or the free base, or a salt or derivative thereof, with one or more equivalents of the appropriate base or acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, eg ethanol, tetrahydrofuran or diethyl ether, which may be removed *in vacuo*, or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.

Pharmaceutically acceptable salts of the compounds of formula I include ammonium salts, alkali metal salts, eg sodium and potassium salts; alkaline earth metal salts, eg the calcium and magnesium salts; salts with organic bases, eg salts with dicyclohexylamine or N-methyl-D-glucamine; and salts with amino acids, eg with arginine, lysine etc. Also, when the molecule contains a basic group, salts with organic or inorganic acids, eg with HCl, HBr, H₂SO₄, H₃PO₄, methanesulfonic, toluensulfonic, maleic, fumaric or camphorsulfonic acids. The non-toxic physiologically acceptable salts are preferred, although other salts are also useful, eg in isolating or purifying the product.

The starting materials for the above processes are either known or may be made from known compounds using conventional processes. Thus compounds of formula II may be made by reaction of a compound of formula IV,

50



IV

55


or a salt thereof,

in which R₃ is as defined above,
 with glyoxylic acid (or & salt, ester, amide or protected derivative thereof)
 eg in an alkanol such as ethanol, at room temperature.

The compounds of formula II may exist in the tautomeric form of formula VII,

5

10



15

or a salt, ester, amide or protected derivative thereof,
 in which R₃ is as defined above.

Compounds of formula III may be made from the appropriate acid or a derivative thereof using conventional processes known per se.

The compounds of formula I, and the intermediates therefor, may be isolated from their reaction mixtures using conventional techniques known per se.

The processes described above may produce the compound of formula I or a derivative thereof. It is also within the scope of this invention to treat any derivative so produced to liberate the free compound of formula I, or to convert one derivative into another.

In addition to the processes described above the compounds of formula I may be made by a variety of processes which are analogous to those known for the production of structurally similar compounds.

We further provide the compounds of formula II and salts, esters, amides and protected derivatives thereof, which are useful as intermediates.

Pharmaceutically acceptable esters include esters with C1 to 10 alcohols, eg alkyl C 1 to 6 esters and esters with benzyl alcohol. The amides may be, for example, unsubstituted or mono- or di- C 1 to 6 alkyl amides and may be made by conventional techniques, eg reaction of an ester of the corresponding acid with ammonia or an appropriate amine.

We prefer those compounds of formula I in which Z is R₂CH(COOH)NH-.

When Z is R₂CH(COOH)NH- we prefer the partial structure -NHCHRCO- to be part of a naturally occurring amino acid. We specifically provide compounds in which Z is R₂CH(COOH)NH- and the two -COOH groups are in different forms, eg where one is esterified and the other is not. We also prefer the group COOH in the substituent Z to be in the form of an ester or amide, eg to be an alkyl C 1 to 6 ester, preferably an ethyl ester.

We further prefer the carbon atom to which the group COOH or its derivative in the substituent Z is attached to be in the S configuration.

Where any of R, R₂, R₃, R₈ or R₁₀ represent alkyl they may individually be straight, branched or cycloalkyl, eg containing up to and including 6 carbon atoms. When R is unsubstituted alkyl C 1 to 6 we prefer R to be methyl. When R is aminoalkyl C 1 to 6 we prefer the NH₂ group to be at the end of an unbranched chain, in particular we prefer R to be the group -CH₂CH₂CH₂CH₂NH₂. We further prefer the carbon atom to which R is attached to be in the S configuration.

When R₂ is alkyl we prefer it to be a straight chain alkyl, preferably a C 1 to 6 alkyl, most preferably n-propyl. When R₂ is phenylalkyl C 7 to 12 we prefer the alkyl chain to comprise 1 to 3 carbon atoms. In particular, when R₂ is phenylalkyl, we prefer R₂ to be phenylethyl.

We prefer R₈ to be alkyl C 1 to 10, more preferably alkyl C 1 to 6 and most preferably methyl.

We prefer R₁₀ to be alkyl C 1 to 6 and more preferably methyl.

Where R₃ represents alkyl it may be straight, branched or cycloalkyl, eg containing up to and including 10 carbon atoms. The term cycloalkyl includes any mono-, bi- or tri-cyclic alkane.

We prefer R₃ to be alkyl C 1 to 10 or cycloalkyl C 3 to 10, more preferably alkyl C 1 to 6 or cycloalkyl C 3 to 6. We particularly prefer R₃ to be either t-butyl or cyclohexyl.

We prefer the -COOH substituent on the thiadiazole ring to be underivatised. We further prefer the asymmetric carbon atom of the Y containing heterocyclic ring to be in the S configuration.

R₁ is preferably hydrogen.

We particularly prefer the specific group of compounds of formula I in which Z is R₂CH(COOH)NH-, R is methyl or aminobutyl, R₂ is n-propyl or phenylethyl and R₃ is t-butyl and pharmaceutically acceptable salts, esters and amides thereof.

5 The preferred salts of the compounds of formula I are maleates, hydrochlorides, ammonium salts or dicyclohexyl-ammonium salts.

The compounds of formula I may contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, eg chromatography or fractional crystallisation. The various optical isomers may be isolated by 10 separation of a racemic or other mixture of the compounds using conventional, eg. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation. We prefer those compounds of formula I in which any asymmetric carbon atoms are in the S configuration.

15 The compounds of the invention are advantageous in that they are more efficacious, produce less side effects, are longer acting, more readily absorbed, less toxic, distributed in the body tissues in a different manner or have other advantageous properties when compared to compounds of similar structure.

20 The compounds of the invention are useful because they possess pharmacological properties. In particular they inhibit angiotensin converting enzyme and thus block conversion of the decapeptide angiotensin I to angiotensin II (see Example A). Angiotensin II is a potent vasoconstrictor in mammals. It also stimulates aldosterone release which results in salt and fluid retention. Increased blood pressure is the physiological result of these changes. Inhibitors of angiotensin converting enzyme are thus effective antihypertensive agents in a variety of animal models (see Example B) and are indicated for use clinically, for example, in patients with renovascular, malignant or essential hypertension or chronic congestive heart failure. See, for example, D W Cushman et al., Biochemistry 16, 5484 (1977) and E W Petillo and M A 25 Ondetti, Med. Res. Rev. 2 93 (1982).

25 Thus, the compounds of this invention are useful as antihypertensives in treating hypertensive mammals, including humans and they can be utilised to achieve reduction of blood pressure, eg in formulations containing appropriate pharmaceutically acceptable excipients, diluents or carriers. The compounds of the invention can be administered (to animals or humans) in unit dosages of 1 to 500mg generally given several times, eg 1 to 4 times, per day thus giving a total daily dose of from 1 to 2000 mg 30 per day. The dose will vary depending on the type and severity of disease, weight of patient and other factors which a person skilled in the art will recognise.

35 The compounds of this invention may be given in combination with other pharmaceutically active compounds, eg diuretics or antihypertensives. The dosage of the other pharmaceutically active compound can be that conventionally used when the compound is administered on its own, but is preferably somewhat lower. To illustrate these combinations, one of the antihypertensives of this invention effective clinically in the range, eg 1-200 milligrams per day, can be combined at levels ranging, eg from 1-200 milligrams per day with the following antihypertensives and diuretics in dose ranges per day as indicated:

40 hydrochlorothiazide (15-200mg), chlorothiazide (125-2000mg), ethacrynic acid (15-200mg), amiloride (5-20mg), furosemide (5-80mg), propanolol (20-480mg), timolol (5-50mg) nifedipine (20-100mg), verapamil (120-480mg) and methyldopa (65-2000mg). In addition, the triple drug combinations of hydrochlorothiazide (15-200mg) plus amiloride (5-20mg) plus converting enzyme inhibitor of this invention (1-200mg) or hydrochlorothiazide (15-200mg) plus timolol (5-50mg), plus the converting enzyme inhibitor of this invention (1-200mg) are contemplated. The above dose ranges may be adjusted on a unit basis as necessary to 45 permit divided daily dosage. Also, the dose may vary depending on the severity of the disease, weight of patient and other factors which a person skilled in the art will recognise.

50 According to our invention we also provide a pharmaceutical composition comprising preferably less than 80%, more preferably less than 50%, eg 1 to 20%, by weight of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

Thus the compound may be put up as a tablet, capsule, dragee, suppository, suspension, solution, injection, implant, a topical, eg transdermal, preparation such as a gel, cream, ointment, aerosol or a polymer system, or an inhalation form, eg an aerosol or a powder formulation.

55 We prefer compositions which are designed to be taken oesophageally and to release their contents in the gastrointestinal tract. Thus we prefer tablets which may, for example, be made by direct compression. In such a process the active ingredient is mixed with one or more of modified forms of starch, calcium phosphate, a sugar eg lactose, microcrystalline cellulose and/or other directly compressible excipients, together with lubricant(s), eg stearic acid or magnesium stearate, flow aid(s), eg talc or colloidal silicon

dioxide, and disintegrant(s), eg starch or the materials sold under the Trade Marks, Nymcel, Ac-Di-Sol, Explotab and Plasdene XL. Tablets are then formed by direct compression, and may be sugar or film coated eg with hydroxypropylmethylcellulose.

- Alternatively the active ingredient may be granulated before tabletting. In such cases the active ingredient is mixed with one or more of starch, calcium phosphate, a sugar eg lactose, microcrystalline cellulose or other suitable excipients and granulated with a binder such as starch, pregelled starch, polyvinylpyrrolidone, gelatine, a modified gelatine, or a cellulose derivative, eg hydroxypropylmethylcellulose. The mass is then dried, sieved and mixed with lubricant(s), flow aid(s) and disintegrant(s), such as described in the previous paragraph. Tablets are then formed by compression of the granules, and may be sugar or film coated, eg with hydroxypropylmethylcellulose.

As a further alternative a powder, blend or granules, such as are described above as intermediates in tabletting, may be filled into a suitable, eg gelatine, capsule.

In order to improve the bioavailability, or decrease variability of availability, of the active ingredient the compound may be:-

- 15 a) dissolved in a suitable solvent, eg polyethylene glycol, Gelucare, arachis oil, a (hydrogenated) vegetable oil or beeswax and the solution is then filled into a gelatine capsule,
- b) produced as a spray-dried or freeze-dried form prior to mixing with other excipients,
- c) milled and/or micronised to produce a powder with a large surface area prior to mixing with other excipients,
- 20 d) made into a solution and distributed over an inert excipient having a large surface area, eg colloidal silicon dioxide. The solvent is evaporated and further excipients added,
- e) formed into a complex with cyclodextrin prior to mixing with other excipients. This complex also assists in increasing light stability, or
- f) made into a solid solution or co-precipitated, eg with polyvinylpyrrolidone, polyethyleneglycol, modified cellulose, hydroxypropylmethylcellulose, urea or a sugar prior to mixing with further excipients.

The compounds, either in their normal form or in a modified form, eg as described immediately above, may be formulated in a controlled release form. Thus the compound may be dispersed, or contained in, a polymer matrix formed from, for example, ethylcellulose, hydroxypropylmethylcellulose or the product sold under the Trade Mark Eudragit. Alternatively the compound may be formulated as a tablet or beads which are surrounded by a semi-permeable membrane, eg shellac, ethylcellulose or an acrylate/methacrylate polymer.

Certain of the compounds of formula I can form hydrates or solvates, eg with an alcohol such as ethanol or, for example when Y is NH can exist in tautomeric forms.

The invention is illustrated, but in no way limited by the following Examples in which temperatures are 35 in degrees centigrade.

Example 1

40 3-[N-(1-(S)-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylic acid

a) Benzyl 2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-carboxylate

A solution of benzenecarbothioic acid hydrazide (2g) and benzyl glyoxylate (2.6g) in ethanol (5ml) was stirred at room temperature for 18 hours under nitrogen. The solvent was removed by evaporation and the residue was flash chromatographed to yield the sub-title product (3.5g) as a beige solid.

A mass spectrum showed M⁺ 298 (base peak 163).

C₁₆H₁₄N₂O₂S requires MWt 298.

50 b) Benzyl 3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-(R)-carboxylate

A stirred mixture of N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine (3.1g) and 1-hydroxybenzotriazole (1.7g) in dichloromethane (100ml) was treated with a solution of the product of step a) (6.85g) in dichloromethane (25ml). A solution of dicyclohexylcarbodiimide (2.26g) in dichloromethane (20ml) was added over 20 minutes and the mixture was stirred at room temperature for 2 days under nitrogen.

The suspended solid was filtered, the filtrate evaporated and the residue was purified by flash chromatography to give the sub-title product (5.23g) as a gum.

A fast atom bombardment mass spectrum showed $M^+ 560$ (base peak 91).
 $C_{31}H_{33}N_3O_5S$ requires MWt 559.

5 c) Benzyl 3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylate

A solution of the product from step b) (0.16g), pyrrolidine (0.16ml) and 3A molecular sieves (0.2g) in acetonitrile (3.2ml) was stirred at room temperature for 3.5 hours. The mixture was poured into water and extracted with ether, dried over magnesium sulphate and evaporated. The residue was flash chromatographed to give the sub-title product (0.05g) as a gum.

10 A fast atom bombardment mass spectrum showed $M^+ 560$ (base peak 91).
 $C_{31}H_{33}N_3O_5S$ requires MWt 559.

15 d) 3-[N-(1-(S)-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylic acid

A solution of the product from step c) (0.26g) in ethanol (20ml) was treated with 10% palladium on charcoal (0.1g) and stirred in a pressure vessel under hydrogen at 3 atmospheres at room temperature for 3 days. The catalyst was filtered off and the filtrate evaporated. The residue was triturated with ether to give 20 the title product (0.08g) as a white solid, m.p. $180.5^\circ - 182^\circ$.

A mass spectrum (FAB) showed $M^+ 470$ (base peak 234).
 $C_{24}H_{27}N_3O_5S$ requires MWt 469.

25 Example 2

2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-phenyl-1,3,4-thiadiazole-2-carboxylic acid

a) Ethyl 2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-carboxylate

30 A solution of benzenecarbothioic acid hydrazide (0.4g) and ethyl glyoxylate (0.4g) in ethanol (1ml) was stirred at room temperature for 2 hours. The solvent was removed by evaporation and the residue re-evaporated with toluene (x2) to yield the sub-title product (0.7g) as a gum.

A mass spectrum showed $M^+ 236$ (base peak 163). $C_{11}H_{12}N_2O_2S$ requires MWt 236.

35 b) Ethyl 3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-carboxylate

A solution of the product of step a) (2.36g) in toluene (100ml) was treated with polyvinylpyridine (2.0g) and 3-acetylthiopropanoyl chloride (1.7g) and the mixture stirred at room temperature for 4 hours. The mixture was filtered and the filtrate stirred with a saturated solution of sodium bicarbonate (100ml) for 1 hour. The organic phase was separated, washed with water, dried and evaporated to a gum. The residue 40 was purified by flash chromatography to give the sub-title product (2.62g) as an oil.

A mass spectrum showed $M^+ 366$ (base peak 163).
 $C_{16}H_{18}N_2O_4S_2$ requires MWt 366.

45 c) 2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-phenyl-1,3,4-thiadiazole-2-carboxylic acid

A solution of the product of step b) (2.6g) in methanol (20ml) was cooled to 0° under nitrogen and treated dropwise with a solution of potassium hydroxide (1.42g) in water (8ml). The mixture was allowed to warm to room temperature over 2 hours and then partitioned between ethyl acetate and water. The aqueous phase was acidified with 2N HCl and the organic phase separated, washed with water and dried. Evaporation yielded an oil which slowly crystallised to give the title product (0.7g) as white crystals. mp 145-6°.

Found: C 48.54, H 4.17, N 9.49, S21.68%

$C_{12}H_{12}N_2O_3S_2$ requires

55 C 48.65, H 4.05, N 9.46, S21.62%

Example 3

5-t-Butyl-3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid

a) Benzyl 5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-carboxylate

5 A solution of t-butylcarbothioic acid hydrazide (0.7g) and benzyl glyoxylate 1g) in ethanol (15ml) was stirred under nitrogen for 16 hours. The solvent was removed by evaporation and the residue was purified by flash chromatography (petroleum ether/ethyl acetate eluent) to yield the sub-title product (1.1g) as a gum.

10 b) Benzyl 5-t-butyl-3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate

15 A stirred mixture of N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine (0.57g) and 1-hydroxybenzotriazole (0.28g) in dichloromethane (40ml) was treated with a solution of the product of step a) (1.14g) in dichloromethane (5ml). Dicyclohexylcarbodiimide (0.42g) was added and the mixture stirred at room temperature for 16 hours under nitrogen. The suspended solid was removed by filtration and the filtrate evaporated to a gum. The residue was purified by flash chromatography to give the sub-title product (0.82g) as an oil.

20 A mass spectrum (FAB) showed M^+ 540 (base peak 91).
 $C_{29}H_{37}N_3O_5S$ requires MWt 539.

25 c) Benzyl 5-t-butyl-3-[N-(1-(S)-ethoxycarbonyl-3-phenyl propyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate

30 A solution of the product from step b) (1.0g) and pyrrolidine (1g) in dry acetonitrile (30ml) was treated with crushed 3A molecular sieves and the mixture stirred at room temperature for 6 hours. The volatile materials were removed by evaporation and the S,S,S isomer separated from the more polar S,S,R isomer by flash chromatography (petroleum ether/ethyl acetate eluent). The sub-title product (0.4g) was isolated as a clear gum.

35 d) 5-t-Butyl-3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid

40 A solution of the product from step c) (0.67g) in ethanol (100ml) was treated with 10% palladium on carbon (0.6g) and the mixture stirred under 1 atmosphere of hydrogen for 16 hours. The catalyst was removed by filtration and the filtrate reduced in volume to ca. 2ml by evaporation. The cooled solution yielded the title product (0.3g) as white crystals, mp 165-8°.

Found: C,58.87; H,6.89; N,9.34; S,7.21%

$C_{22}H_{31}N_3O_5S$ requires

C,58.80; H,6.90; N,9.35; S,7.13%

A mass spectrum (FAB) showed M^+ 450 (base peak 234).

45 $C_{22}H_{31}N_3O_5S$ requires MWt 449.

Example 4

5-t-Butyl-3-[N²-(1-(S)-carboxy-3-phenylpropyl)-L-lysyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid

50 a) Benzyl 2-hydroxy-4-phenylbutanoate

55 A solution of 2-hydroxy-4-phenylbutanoic acid (20.4g), triethylamine (15.9ml) and benzyl bromide (12.75ml) in ethyl acetate (64ml) was heated under reflux for 16 hours. The solution was cooled and poured into a mixture of water and ether. The separated organic extract was washed with saturated sodium bicarbonate solution and water, dried over magnesium sulphate and filtered. The filtrate was evaporated and the residue purified by flash chromatography (petroleum ether/ethyl acetate eluent) to yield the sub-title product as a yellow oil (14g).

A mass spectrum showed $M^+ 270$ (base peak 91).
 $C_{17}H_{18}O_3$ requires MWt 270

b) N⁶-Benzylcarbonyl,1-N²-(1-(S)-benzyloxycarbonyl-3-phenylpropyl)-L-lysine hydrochloride

5 A solution of the product from step a)(13.8g) and pyridine (6.6ml) in dichloromethane (136ml) was added over 0.5 hours under nitrogen to a stirred solution of trifluoromethanesulphonic anhydride (12.9ml) in dichloromethane (136ml) cooled to 5 °C. After a further 0.5 hours the solution was washed with water, dried over magnesium sulphate, filtered and the filtrate evaporated.

10 The residue was taken up in dichloromethane (136ml) and added to a solution of N⁶-benzyloxycarbonyl-L-lysine t-butyl ester (15.5g) and triethylamine (6.5ml) in dichloromethane (136ml). The mixture was stirred at room temperature for 1 hour, heated under reflux for 2.5 hours, cooled, washed with water, dried over magnesium sulphate and filtered. The filtrate was evaporated and the residue purified by flash chromatography (ether/petroleum ether eluent) to separate and isolate the more polar SS isomer.

15 A solution of the SS t-butyl ester (0.5g) in ether (15ml) was cooled to +5 ° and saturated with hydrogen chloride for 2 hours. The solution was stirred at room temperature for a further 18 hours and the solvent was then removed by evaporation. Trituration of the residue in ether gave the sub-title product as a white solid (0.39g).

A fast atom bombardment mass spectrum showed $M^+ 533$ (base peak 91).

20 $C_{31}H_{36}N_2O_6$ requires MWt 532.

c) Benzyl 3-[N⁶-benzyloxycarbonyl-N²-(1-(S)-benzyloxycarbonyl-3-phenylpropyl)-L-lysyl]-5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate

25 A stirred solution of the SS product from step b) (5.68g) and 1-hydroxybenzotriazole (1.35g) in dichloromethane (85ml) was treated with a solution of the product of Example 4, step a) (5.87g) in dichloromethane (60ml). A solution of dicyclohexylcarbodiimide (2.1g) in dichloromethane (85ml) was added over 5 minutes and the mixture was stirred at room temperature for 18 hours under nitrogen. Triethylamine (1.4ml) was added and the suspended solid removed by filtration. The filtrate was evaporated and the residue purified by flash chromatography to give the sub-title product as an oil (2.1g).

30 A fast atom bombardment mass spectrum showed $M^+ 793$ (base peak 91).

$C_{45}H_{52}N_4O_7S$ requires MWt 792.

d) Benzyl 3-[N⁶-benzyloxycarbonyl-N²-(1-(S)-benzyloxycarbonyl-3-phenylpropyl)-L-lysyl]-5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate

35 A solution of the product of step c) (2.1g) and pyrrolidine (1.6ml) in dry acetonitrile (60ml) was treated with crushed 3A molecular sieves and the mixture stirred at room temperature for 24 hours under nitrogen. The volatile materials were removed by evaporation and the SSS isomer separated from the more polar

40 SSR isomer by flash chromatography. The SSS sub-title product (0.47g) was isolated as a clear oil.

A fast atom bombardment mass spectrum showed $M^+ 793$ (base peak 91).

$C_{45}H_{52}N_4O_7S$ requires MWt 792.

e) 5-t-Butyl-3-[N²-(1-(S)-carboxy-3-phenylpropyl)-L-lysyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid

45 A solution of the product from step d) (1.1g) in ethanol (90ml) was treated with 10% palladium on carbon (0.9g) and the mixture stirred under 1 atmosphere of hydrogen for 1 hour. The catalyst was removed by filtration and the filtrate evaporated. The residue was recrystallised from a mixture of tetrahydrofuran and ethanol to give the title product as a white solid (0.24g) mp slowly decomposes at 180 - 190 °.

50 Found: C 55.86 H 6.97 N 11.24 S 6.56 H2O 2.83

$C_{23}H_{34}N_4O_5S$. 0.77H₂O

Requires: C 56.11 H 7.23 N 11.39 S 6.51 H2O 2.82

A fast atom bombardment mass spectrum showed $M^+ 479$ (base peak 84).

$C_{23}H_{34}N_4O_5S$ requires MWt 478.

55

Example 5

5-t-Butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid

a) Ethyl 2-[(trifluoromethane)sulphonyloxy]pentanoate

Under nitrogen, a solution of pyridine (11.9g) in dry dichloromethane (500ml) was rapidly stirred at -22° while trifluoromethane sulphonic anhydride (40.5g) was added dropwise. After the addition, the white slurry was stirred at -22° for 15 minutes and then a solution of ethyl 2-hydroxy pentanoate (16.8g) in dichloromethane was added over 2 minutes at this temperature. The temperature was then allowed to rise to room temperature and the mixture was stirred vigorously for 1 hour, after which time the white solid was filtered off, washed well with dichloromethane and the combined washings and filtrate were evaporated to dryness. The oily solid obtained was taken up in 60 - 80° petroleum ether and was passed down a short pad of silica, eluting with more petroleum ether. The petroleum ether solution was evaporated to dryness leaving an oil (23.4g)

NMR, CDCl₃,delta: 1.0(3H,t,) 1.32(3H,t,) 1.5(2H,m), 2.0(2H,m), 4.3(2H,m) 5.12(1H,t)

b) N-(1-Ethoxycarbonylbutyl)-L-alanine benzyl ester

L-Alanine benzyl ester hydrochloride (10.0g) was converted to the free-base in dichloromethane using triethylamine. The resulting mixture was evaporated to dryness and the residue was slurried with several portions of diethyl ether. The combined ether solutions were evaporated to dryness leaving the free-base as an oil.

The oil was dissolved in dichloromethane (200ml) and triethylamine (7.2g) was added. The resulting solution was stirred under nitrogen at room temperature while a solution of the product from step a) (12.8g) in dichloromethane was added dropwise over 30 minutes. The resulting mixture was stirred for 2 hours at room temperature, for 2 hours at reflux and then was evaporated to dryness leaving an oily residue which was purified by flash chromatography on silica eluting with 60 - 80° petroleum ether/diethyl ether 5:1 to give the R,S, (4.8g, 34%) and S,S, (4.7g, 33%) diastereoisomer in order of elution

R,S

NMR CDCl₃,delta, 0.9(3H,t), 1.24(3H,t), 1.30(3H,d) 1.38(2H,m), 1.6(2H,m), 3.27(1H,t) 3.4(1H,q), 4.12(2H,m), 5.15(2H,q), 7.35(5H,s).

S,S

NMR CDCl₃,delta: 0.9(3H,t); 1.28(3H,t); 1.38(3H,d); 1.3-1.8(4H,m); 3.28(1H,t); 3.4(1H,q); 4.18(2H,m); 5.17(2H,q); 7.35(5H,s).

c) N-(1(S)-Ethoxycarbonylbutyl)-L-alanine

The S,S diastereoisomer benzylester from step b) (6.2g) in ethanol (250ml) was hydrogenated at 3 atmospheres at room temperature for 30 minutes over 10% palladium on charcoal (0.6g). The catalyst was removed by filtration and the filtrate was evaporated to near dryness. The residue was slurried with diethyl ether and the white solid was filtered off and was dried to give the required product (3.8g) mp 153 - 4°.

Found: C,55.62; H, 8.47; N, 6.32%

C₁₀H₁₉NO₄ requires

C,55.29; H,8.75; N,6.45%

d) Benzyl 5-t-butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate

Under nitrogen at room temperature a mixture of the S,S amino acid from step c) (0.62g) and 1-hydroxybenzotriazole (0.45g) in dry dichloromethane (125ml) was stirred for 30 minutes with benzyl 5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-carboxylate (1.6g). Dicyclohexylcarbodiimide (0.6g) was then added and the resulting mixture was stirred for 18 hours, filtered and the filtrate evaporated to dryness. The residue was purified by column chromatography on silica eluting with diethyl ether/petroleum ether (60 - 80°), 1:1 to give the required diester as an oil (1.1g)

NMR CDCl₃,delta: 0.9(3H,t), 1.2-1.7(19H,m), 3.3(1H,t) 4.2(3H,m), 5.2(2H,q), 6.18(1H,s) 7.35(5H,s).

e) Benzyl 5-t-butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate

Under nitrogen, pyrrolidine (1.5ml) was added to a solution of the 'S,S,R' ester (step d) (1.6g) in dry acetonitrile and the resulting solution was stirred at room temperature for 24 hours. The 1:1 mixture of S,S,R and S,S,S esters so produced was separated by flash chromatography on silica eluting with ethyl acetate/petroleum ether 60 - 80°, 1:3 to give 0.65g of each isomer. The S,S,R isomer was recycled such that the total conversion was 81%.

5 NMR CDCl₃delta: 0.9(3H,t), 1.2-1.7(19H,m), 3.3(1H,t) 4.2(3H,m), 5.17(2H,s), 6.18(1H,s) 7.35(5H,s).

f) 5-t-Butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2, 3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid

10 The S,S,S benzyl ester from step e) (1.8g) in ethanol (500ml) was hydrogenated over 10% Pd on charcoal (1.8g) at atmospheric pressure and room temperature for 5 hours. The catalyst was removed by filtration and the filtrate was evaporated to dryness. The residue was triturated with a 1:1 mixture of ether/petroleum ether 60 - 80° to give the required acid as a white solid (1.3g). mp 183 - 5°.

Found: C, 47.13; H, 7.89; N, 9.31; S, 7.12%

15 C₁₇H₂₉N₃O₅S. 2.5 H₂O requires
C, 47.22; H, 7.87; N, 9.72; S, 7.41%

Example 6

20 Ammonium 2,3-dihydro-3-(3-mercaptopro-2-(S)-methyl-1-oxopropyl)-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylate monohydrate

a) Benzyl 3-(3-acetylthio-2-(S)-methyl-1-oxopropyl)-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-carboxylate

25 3-Acetylthio-2-(S)-methylpropanoyl chloride (2.3g) in dichloromethane (30ml) was added over 5 minutes to a stirred mixture of the product of Example 1, step a) (3.6g) and polyvinylpyridine (2.4g) in dichloromethane (60ml). The mixture was stirred at room temperature for 20 hours and 3-acetylthio-2-(S)-methylpropanoyl chloride (1.2g) was then added. The mixture was stirred for a further 2 hours, filtered and the filtrate stirred with a saturated solution of sodium bicarbonate for 1 hour. The organic phase was 30 separated, washed with water, dried and evaporated to a gum. The residue was purified by flash chromatography to give the sub-title product (4.4g) as an oil.

b) Ammonium 2,3-dihydro-3-(3-mercaptopro-2-(S)-methyl-1-oxopropyl)-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylate

35 A solution of the product of step a) (2.8g) in methanol (50ml) under nitrogen was treated dropwise with a solution of potassium hydroxide (1.3g) in water (100ml). The mixture was stirred for a further 4 hours and then partitioned between ether and water. The separated aqueous phase was acidified with 2N HCl and extracted with ether. The organic phase was washed with water, dried and evaporated to an oil. The residue 40 was purified by reverse phase HPLC to give the title product (0.023g) as a white solid. mp 194-7°.

A mass spectrum showed M⁺ 310 (base peak 163).

C₁₃H₁₄N₂O₃S₂ Requires MW_t 310.

Example 7

45 2,3-Dihydro-3-(3-mercaptopro-1-oxopropyl)-5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazole-2-carboxylic acid

a) 4-(Trifluoromethyl)phenylcarbothioic acid hydrazide

50 [((4-(Trifluoromethyl)phenyl)thioxomethyl)thio]acetic acid (6.7g) was dissolved in methanol (50ml). Potassium hydroxide (1.34g) in water (15ml) was added followed by hydrazine hydrate (1.28ml). The mixture was stirred for 4 hours at room temperature. Glacial acetic acid was added until the pH was 5 and the solvent was removed under reduced pressure. The product was extracted with diethyl ether (250ml) and the solvent 55 was evaporated under reduced pressure. The resulting solid was crystallised from cyclohexane as pale pink crystals (4.0g) mp 114-115.5°.

b) Benzyl 2,3-dihydro-5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazole-2-carboxylate

Benzyl glyoxylate (0.8g) was added to a solution of the product from step a) (1.0g) in dry ethanol (30ml). The mixture was stirred at room temperature under an atmosphere of nitrogen for 5 hours. The solvent was removed under reduced pressure and the product was crystallised from ethanol to yield the sub-title product (1.4g) as white crystals. mp 99-100.5°.

5

c) Benzyl 3-[3-acetylthio-1-oxopropyl]-2,3-dihydro-5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazole-2-carboxylate

3-Acetylthiopropanoyl chloride (0.36g), poly (4-vinyl pyridine) (0.89) and the product from step b) (0.89) were stirred together in dry toluene (30ml) under an atmosphere of nitrogen for 20 hours. Diethyl ether was added and the solid was filtered off and washed with diethyl ether. The filtrate was evaporated under reduced pressure and the resulting product was crystallised from ethanol to yield the sub-title product (0.9g) as a white solid. mp 120-121°.

15 d) 2,3-Dihydro-3-(3-mercaptopro-1-oxopropyl)-5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazole-2-carboxylic acid

Potassium hydroxide in methanol (1M, 4.9ml) was added to a solution of the product from step c) (0.81g) in methanol (10ml) and water (5ml). The mixture was stirred under an atmosphere of nitrogen for 2 hours. Glacial acetic acid was added and the solvent was removed under reduced pressure. The product was purified by flash chromatography using 1% acetic acid/99% ethyl acetate as eluent to yield the title compound (0.23g) as a fawn solid. mp softens 93-95°.

A mass spectrum showed M+ 364 (base peak 231)

C₁₃H₁₁F₃N₂O₃S₂ requires MWt 364.

The following compounds were prepared from the appropriate starting materials by the processes described in Example 5.

Example 8

5-t-Butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylic acid

30

mp 67-9°

Found: C,48.37; H,7.99; N,9.42; S,7.2%

C₁₇H₂₉N₃O₅S. 2H₂O requires

C,48.22; H,7.80; N,9.93; S,7.57%

35 The following compounds were prepared by the method of Example 2 using appropriate starting materials

Example 9

5-t-Butyl-2,3-dihydro-3-(3-mercaptopro-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid

mp 128°

Example 10

2,3-Dihydro-3-(3-mercaptopro-1-oxopropyl)-5-(4-methoxyphenyl)-1,3,4-thiadiazole-2-carboxylic acid

mp 164°

50 Example 11

2,3-Dihydro-3-(3-mercaptopro-1-oxypropyl)-5-(2-methyl phenyl)-1,3,4-thiadiazole-2-carboxylic acid

mp 118-120°

55

Example 12

5-(Furan-2-yl)-2,3-dihydro-3-(3-mercaptopro-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid

mp 105-108°.

Example 13

5 Ethyl 3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-(naphthalen-2-yl)-1,3,4-thiadiazole-2-carboxylate

a) Naphthalene-2-carbothioic acid hydrazide

The sub-title product was prepared from appropriate starting materials by the processes of Example 7,
10 steps 5 a), b), c) and d). mp 166-167°

b) Ethyl 2,3-dihydro-5-(naphthalen-2-yl)-1,3,4-thiadiazole-2-carboxylate

Prepared from the product of step a) and ethyl glyoxylate by the process of Example 3, step a). The 10
15 crude product was used without further purification.

c) Ethyl 3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-(naphthalen-2-yl)-1,3,4-thiadiazole-2-carboxylate

Prepared from the crude product of step b) and 3-acetylthiopropanoyl chloride by the process of
20 Example 15 3, step b). mp 107-108°

Mass spectrum (FAB) showed M^+ 417 (base peak 213). $C_{20}H_{20}N_2O_4S_2$ requires MWt 416.

Example 14

25 5-(Adamant-1-yl)-2,3-dihydro-3-(3-mercaptopro-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid

a) Methyl 1-adamantanecarbodithioate

A mixture of 1-adamantanecarboxylic acid chloride (9.0g) and 2,4-bis-methylthio-1,2,3,4-
30 dithiaphosphetan-2,4-disulphide(12.9g) in dry benzene was heated under reflux for 5 hours. The solvent
was evaporated and the residue purified by flash chromatography to give the sub-title product (6.2g) as a
yellow solid.

mp 64.5-66°

35 b) Adamantane-1-carbothioic acid hydrazide

A solution of the product of step a) (1g) in methanol (50ml) was treated with hydrazine hydrate (0.3g)
and the mixture stirred at room temperature for 1 hour. The solvent was evaporated, the residue triturated
with water, and the pH adjusted to 7 to give the sub-title product (0.8g) as a white solid.

40 mp 204-206°

c) Ethyl 5-(adamant-1-yl)-2,3-dihydro-1,3,4-thiadiazole-2-carboxylate

The product of step b) was treated with ethyl glyoxylate by the process of Example 3, step a) to give
45 the sub-title product (1.5g) as an oil.

d) Ethyl 5-(adamant-1-yl)-2,3-dihydro-3-(3-mercaptopro-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylate

The crude product of step c) was treated with 3-acetylthiopropanoyl chloride by the process of Example
50 3, step b) to give the sub-title product as an oil.

Mass spectrum (FAB) showed M^+ 425 (base peak 221).

$C_{20}H_{28}N_2O_4S_2$ required MWt 424.

e) 5-(Adamant-1-yl)-2,3-dihydro-3-(3-mercaptopro-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid

55 The product of step d) was treated with potassium hydroxide by the process of Example 3, step c) to
give the title product as white solid. mp 183-184°

Mass spectrum (FAB) showed M^+ 355 (base peak 221).

$C_{16}H_{22}N_2O_3S_2$ requires MWt 354.

Example 15

5 2,3-Dihydro-3-(3-mercaptopro-1-oxopropyl)-5-methyl-1,3,4-thiadiazole-2-carboxylic acid dicyclohexylamine salt

A solution of dicyclohexylamine (0.5ml) in ether 10 (10ml) was added to a solution of 2,3-dihydro-3-(3-mercaptopro-1-oxopropyl)-5-methyl-1,3,4-thiadiazole-2-carboxylic acid (0.5g) (prepared from appropriate starting materials by the method of Example 3) in ether (20ml). The solvent was removed by evaporation.

10 Trituration of the residue with ether gave the title compound as a white solid (0.5g). mp 150-153°.

The following compounds were prepared by the method of Example 36 using appropriate starting materials

Example 16

15 5-Cyclohexyl-2,3-dihydro-3-(3-mercaptopro-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid dicyclohexylamine salt

mp 174-6°.

20 Example 17

2,3-Dihydro-3-(3-mercaptopro-1-oxopropyl)-5-methylthio-1,3,4-thiadiazole-2-carboxylic acid dicyclohexylamine salt

25 mp 150-3°.

Example A

30 In vitro Assay of inhibitors of Angiotensin Converting Enzyme

The method is based upon that of Cushman and Cheung (1971) but uses a radioactive substrate [glycine-1-¹⁴C] hippuryl-L-histidyl-L-leucine (HHL) whose hydrolysis may be determined by liquid scintillation counting of released [¹⁴C]-hippuric acid. Hydrolysis of 2mM HHL by an extract of rabbit lung acetone powder (Sigma) over a 30 min. incubation period at 37° is followed by acidification of the reaction mixture and extraction of [¹⁴C]hippurate with ethyl acetate.

Potential inhibitors are tested initially at 0.01mM and if found active are retested at lower concentrations to determine an IC₅₀. Dimethyl sulphoxide at 1% final concentration may be used as a solubility aid without affecting enzyme activity. Compounds of special interest are studied at a range of substrate and inhibitor concentrations to determine the type of inhibition and are also tested against other enzymes, eg carboxypeptidase A to establish their specificity for ACE.

Example B

45 Antihypertensive effects were investigated in conscious spontaneously hypertensive rats (SHR) of the Okamoto strain. Systolic blood pressure and heart rate were measured by the tail cuff method using an electrosphygmomanometer 1 hour before and 1, 3, 5 and 24 hours after oral dosing with the compound (dose range 0.1 - 100 mg/kg p.o.). Percentage changes in each parameter were measured with respect to pretreatment control values.

50 Example C

	% w/w	Range % w/w
5	Compound of formula I	5 1-20
	Microcrystalline cellulose	50 10-80
	Spray dried lactose	37.75 10-80
	Magnesium stearate	1 0.25-2
	Colloidal silicon dioxide	0.25 0.1-1
10	Cross linked sodium carboxy methyl cellulose	3 1-5
	Hydroxypropylmethylcellulose (coating)	3 1-5

This formulation is made up as a direct compression tablet, or without compression or coating, may be filled into a gelatine capsule.

15 Example D


	% w/w	Range % w/w
20	Compound of formula I	5 1-20
	Microcrystalline cellulose	50 10-80
	Lactose	35.75 10-80
	Polyvinylpyrrolidone	2 1-5
	Magnesium stearate	1 0.25-2
25	Colloidal silicon dioxide	0.25 0.1-1
	Cross linked sodium carboxy methyl cellulose	3 1-5
	Hydroxypropyl methyl cellulose (coating)	3 1-5

30 This formulation is made up as a granulate and then compressed into a tablet. Alternatively the granules may be filled into a gelatine capsule.

Claims

1. A compound of formula I

35



in which R₃ is alkyl C1 to 10, cycloalkyl C3 to 10, SR₁₀, furanyl, phenyl or phenylalkyl C7 to 12, naphthalenyl, the phenyl group optionally being substituted by alkyl C1 to 6, or alkoxy C1 to 6,

R₁₀ is alkyl C1 to 10,

50 R is hydrogen, alkyl C1 to 10 or alkyl C1 to 6 substituted by NH₂,

Z is R₂CH(COOH)NH- or R₁SCH₂-,

R₁ is hydrogen or R₈CO-

R₈ is alkyl C1 to 10 or phenyl, and

R₂ is alkyl C1 to 10 or phenylalkyl C7 to 12.

55 and pharmaceutically acceptable salts, esters and amides thereof.

2. A compound according to Claim 1, wherein Z is R₂CH(COOH)NH- and R₃ is alkyl C1 to 10 or cycloalkyl C3 to 10.


3. A compound according to Claim 2 wherein
 Z is $R_2\text{CH}(\text{COOH})\text{NH}-$,
 R is methyl or aminobutyl,
 R_2 is n-propyl or phenylethyl,
 5 R_3 is t-butyl, and
 all asymmetric carbon atoms are in the S configuration.
4. 5-t-Butyl-3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid,
 10 5-t-Butyl-3-[N²-(1-(S)-carboxy-3-phenylpropyl)-L-lysyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid, and
 5-t-Butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylic acid,
 15 and pharmaceutically acceptable salts thereof.
- 15 5. 3-[N-(1(S)-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylic acid,
 Benzyl 3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-(R)-carboxylate,
 20 Benzyl 3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylate,
 2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-phenyl-1,3,4-thiadiazole-2-carboxylic acid,
 Ethyl 3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-carboxylate,
 25 Benzyl 5-t-butyl-3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate,
 Benzyl 5-t-butyl-3-[N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate,
 30 Benzyl 3-[N⁶-benzyloxycarbonyl-N²-(1-(S)-benzyloxycarbonyl-3-phenylpropyl)-L-lysyl]-5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate,
 Benzyl 3-[N⁶-benzyloxycarbonyl-N²-(1-(S)-benzyloxycarbonyl-3-phenylpropyl)-L-lysyl]-5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate,
 35 Benzyl 5-t-butyl-3-(N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl)-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate,
 Benzyl 5-t-butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate,
 40 2,3-Dihydro-3-(3-mercaptop-2-(S)-methyl-1-oxopropyl)-5-phenyl-1,3,4-thiadiazole-2-(S)-carboxylic acid,
 Benzyl 3-(3-acetylthio-2-(S)-methyl-1-oxopropyl)-2,3-dihydro-5-phenyl-1,3,4-thiadiazole-2-carboxylate,
 45 Benzyl 3-[3-acetylthio-1-oxopropyl]-2,3-dihydro-5-[4 (trifluoromethyl)phenyl]-1,3,4-thiadiazole-2-carboxylate,
 5-t-Butyl-3-[N-(1-(S)-ethoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylic acid,
 50 5-t-Butyl-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid,
 2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-(4-methoxyphenyl)-1,3,4-thiadiazole-2-carboxylic acid,
 2,3-Dihydro-3-(3-mercaptop-1-oxypropyl)-5-(2-methylphenyl)-1,3,4-thiadiazole-2-carboxylic acid,
 5-(Furan-2-yl)-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid,
 55 Ethyl 3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-(naphthalen-2-yl)-1,3,4-thiadiazole-2-carboxylate,
 5-(Adamant-1-yl)-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid,
 Ethyl 5-(adamant-1-yl)-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylate,
 2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-methyl-1,3,4-thiadiazole-2-carboxylic acid,
 5-Cyclohexyl-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazole-2-carboxylic acid,
 2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-methylthio-1,3,4-thiadiazole-2-carboxylic acid,
 and pharmaceutically acceptable salts thereof.
6. The use of a compound of formula I, as defined in Claim 1, in the production of a pharmaceutical

formulation for the treatment of a hypertensive condition.

7. A process for the production of a compound of formula I, as defined in Claim 1, or a pharmaceutically acceptable salt, ester or amide thereof, which comprises

- 5 a) removal of a protecting group from a compound of formula I in which one or more of the amino or carboxylic acid groups is protected, or
 b) reaction of a compound of formula II,

10



II

15

or a salt, ester, amide, tautomer, or protected derivative thereof,
 20 in which R₃ as defined in Claim 1 with a compound of formula III,

ZCHR₂COX III

in which Z and R₂ are as defined in Claim 1, and X is a good leaving group,

- 25 c) conversion of a compound of formula I, as defined in Claim 1, in which the asymmetric carbon atom of the thiadiazole ring is in the R configuration into a corresponding compound in which that carbon atom is in the S configuration,
 d) reaction of a compound of formula II, in which R₃, Y and n are as defined in Claim 1,
 with a compound of formula VI,

30


ZCHR₂COOH VI

in which Z and R₂ are as defined in Claim 1,

- 35 e) production of a pharmaceutically acceptable salt of a compound of formula I, as defined in Claim 1, by treating a compound of formula I as defined in Claim 1,
 or another salt, an ester or an amide thereof,
 with a compound containing an available
 pharmaceutically acceptable ion and capable of converting the compound of formula I or the other
 salt, ester or amide thereof, to a pharmaceutically acceptable salt of the compound of formula I,
 40 and where desired or necessary deprotecting the resulting compound, or converting a compound of
 formula I to a pharmaceutically acceptable salt, ester or amide thereof or vice versa.

8. A compound of formula II,

45



II

50

55 in which

R₃ is hydrogen, alkyl C₁ to 10, cycloalkyl C₃ to 10, SR₁₀, furanyl, phenyl or phenylalkyl C₇ to 12, naphthalenyl the phenyl group optionally being substituted by alkyl C₁ to 6, or alkoxy C₁ to 6,
 R₁₀ is alkyl C₁ to 10, and

and salts, esters, amides and tautomers thereof.

9. A compound according to Claim 1 for use as a pharmaceutical.
 5 10. A pharmaceutical formulation comprising a compound according to Claim 1 in admixture with a pharmaceutically acceptable diluent, excipient or carrier.

Revendications

- 10 1. Composé de formule I



20 où R₃ est alcoyle en C1 à 10, cycloalcoyle en C3 à 10, SR₁₀, furannyle, phényle ou phénylalcoyle en C7 à 12, naphtalényle, le radical phényle étant facultativement substitué par alcoyle en C1 à 6, ou alcoxy en C1 à 6,

R₁₀ est alcoyle en C1 à 10,

25 R est hydrogène, alcoyle en C1 à 10 ou alcoyle en C1 à 6 substitué par NH₂,

Z est R₂CH(COOH)NH- ou R₁SCH₂-,

R₁ est hydrogène ou R₈CO-

R₈ est alcoyle en C1 à 10 ou phényle, et

30 R₂ est alcoyle en C1 à 10 ou phénylalcoyle en C7 à 12, et les sels, esters et amides pharmaceutiquement acceptables de celui-ci.

2. Composé suivant la revendication 1,

où Z est R₂CH(COOH)NH-, et

R₃ est alcoyle en C1 à 10 ou cycloalcoyle en C3 à 10.

35

3. Composé suivant la revendication 2,

où Z est R₂CH(COOH)NH-,

R est méthyle ou aminobutyle,

R₂ est n-propyle ou phényléthyle,

40

R₃ est t-butyle, et

tous les atomes de carbone asymétriques sont dans la configuration S.

4. L'acide 5-t-butyl-3-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylique,

45 l'acide 5-t-butyl-3-[N²-(1-(S)-carboxy-3-phénylpropyl)-L-lysyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylique, et

l'acide 5-t-butyl-3-[N-(1-(S)-éthoxy-carbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylique,

outre les sels pharmaceutiquement acceptables de ceux-ci.

50

5. L'acide 3-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2,3-dihydro-5-phényl-1,3,4-thiadiazole-2-(S)-carboxylique,

le 3-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2,3-dihydro-5-phényl-1,3,4-thiadiazole-2-(R)-carboxylate de benzyle,

55 le 3-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2,3-dihydro-5-phényl-1,3,4-thiadiazole-2-(S)-carboxylate de benzyle,

l'acide 2,3-dihydro-3-(3-mercaptopropanoyl)-5-phényl-1,3,4-thiadiazole-2-carboxylique,

le 3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-phényl-1,3,4-thiadiazole-2-carboxylate d'éthyle,

le 5-t-butyl-3-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate de benzyle,

le 5-t-butyl-3-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate de benzyle,

5 le 3-[N⁶-benzyloxycarbonyl-N²-(1-(S)-benzyloxycarbonyl-3-phénylpropyl)-L-lysyl]-5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate de benzyle,

10 le 3-[N⁶-benzyloxycarbonyl -N²-(1-(S)-benzyloxycarbonyl-3-phénylpropyl)-L-lysyl]-5-t-butyl-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate de benzyle,

le 5-t-butyl-3-[N-(1-(S)-éthoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylate de benzyle,

15 le 5-t-butyl-3-[N-(1-(S)-éthoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylate de benzyle,

l'acide 2,3-dihydro-3-(3-mercaptopropanoate)-5-phényle-1,3,4-thiadiazole-2-(S)-carboxylique,

15 le 3-(3-acétylthio-2-(S)-méthyl-1-oxopropyl)-2,3-dihydro-5-phényle-1,3,4-thiadiazole-2-carboxylate de benzyle,

l'acide 2,3-dihydro-3-(3-mercaptopropanoate)-5-[4-(trifluorométhyl)phényle]-1,3,4-thiadiazole-2-carboxylique,

20 le 3-[3-acétylthio-1-oxopropyl]-2,3-dihydro-5-[4-(trifluorométhyl)phényle]-1,3,4-thiadiazole-2-carboxylate de benzyle,

l'acide 5-t-butyl-3-[N-(1-(S)-éthoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(R)-carboxylique,

l'acide 5-t-butyl-2,3-dihydro-3-(3-mercaptopropanoate)-1,3,4-thiadiazole-2-carboxylique,

l'acide 2,3-dihydro-3-(3-mercaptopropanoate)-5-(4-méthoxyphényle)-1,3,4-thiadiazole-2-carboxylique,

25 que,

l'acide 2,3-dihydro-3-(3-mercaptopropanoate)-5-(2-méthylphényle)-1,3,4-thiadiazole-2-carboxylique,

l'acide 5-(furann-2-yl)-2,3-dihydro-3-(3-mercaptopropanoate)-1,3,4-thiadiazole-2-carboxylique,

le 3-(3-acétylthio-1-oxopropyl)-2,3-dihydro-5-(naphtalén-2-yl)-1,3,4-thiadiazole-2-carboxylate d'éthyle,

30 l'acide 5-(adamant-1-yl)-2,3-dihydro-3-(3-mercaptopropanoate)-1,3,4-thiadiazole-2-carboxylique,

le 5-(adamant-1-yl)-2,3-dihydro-3-(3-mercaptopropanoate)-1,3,4-thiadiazole-2-carboxylate d'éthyle,


l'acide 2,3-dihydro-3-(3-mercaptopropanoate)-5-méthyl-1,3,4-thiadiazole-2-carboxylique,

l'acide 5-cyclohexyl-2,3-dihydro-3-(3-mercaptopropanoate)-1,3,4-thiadiazole-2-carboxylique,

35 l'acide 2,3-dihydro-3-(3-mercaptopropanoate)-5-méthylthio-1,3,4-thiadiazole-2-carboxylique, autre les sels pharmaceutiquement acceptables de ceux-ci.

6. Utilisation d'un composé de formule I, tel que défini dans la revendication 1, dans la production d'une composition pharmaceutique pour le traitement d'un état d'hypertension.
- 40 7. Procédé de production d'un composé de formule I, tel que défini dans la revendication 1, ou d'un sel, ester ou amide pharmaceutiquement acceptable de celui-ci, qui comprend
- a) l'élimination d'un radical protecteur d'un composé de formule I où un ou plusieurs des radicaux amino ou acide carboxylique sont protégés, ou
- b) la réaction d'un composé de formule II,

45



- 55 ou d'un sel, ester, amide, tautomère ou dérivé protégé de celui-ci,
où R₃ est tel que défini dans la revendication 1,
avec un composé de formule III

ZCHRCOX III

où Z et R sont tels que définis dans la revendication 1, et X est un bon radical partant,
 5 c) la conversion d'un composé de formule I, tel que défini dans la revendication 1, où l'atome de carbone asymétrique du cycle thiadiazole est dans la configuration R, en un composé correspondant où cet atome de carbone est dans la configuration S,
 d) la réaction d'un composé de formule II, où R₃, Y et n sont tels que définis dans la revendication 1,
 avec un composé de formule VI,


ZCHR₃COOH VI

où Z et R sont tels que définis dans la revendication 1,

e) la production d'un sel pharmaceutiquement acceptable d'un composé de formule I, tel que défini dans la revendication 1, par traitement d'un composé de formule I, tel que défini dans la revendication 1,

ou d'un autre sel, d'un ester ou d'un amide de celui-ci, à l'aide d'un composé contenant un ion pharmaceutiquement acceptable et capable de convertir le composé de formule I ou l'autre sel, l'ester ou l'amide de celui-ci en un sel pharmaceutiquement acceptable du composé de formule I, et lorsque la chose est souhaitée ou nécessaire, la déprotection du composé résultant ou la conversion d'un composé de formule I en un sel, ester ou amide pharmaceutiquement acceptable de celui-ci et vice versa.

8. Composé de formule II,



35 où R₃ est hydrogène, alcoyle en C1 à 10, cycloalcoyle en C3 à 10, SR₁₀, furannyle, phényle ou phénylalcoyle en C7 à 12, naphtalényle, le radical phényle étant facultativement substitué par alcoyle en C1 à 6, ou alcoxy en C1 à 6,

R₁₀ est alcoyle en C1 à 10,


et les sels, esters, amides et tautomères de celui-ci.

40 9. Composé suivant la revendication 1, à utiliser comme agent pharmaceutique.

45 10. Composition pharmaceutique comprenant un composé suivant la revendication 1 en mélange avec un diluant, excipient ou porteur pharmaceutiquement acceptable.

Patentansprüche

1. Verbindung der Formel (I)



worin R_3 C₁-C₁₀-Alkyl, C₃-C₁₀-Cycloalkyl, SR₁₀, Furanyl, Phenyl, C₇-C₁₂-Phenylalkyl oder Naphthalinyl bedeutet, wobei die Phenylgruppe gegebenenfalls durch C₁-C₆-Alkyl oder C₁-C₆-Alkoxy substituiert ist, R₁₀ C₁-C₁₀-Alkyl bedeutet, R Wasserstoff, C₁-C₁₀-Alkyl oder mit NH₂ substituiertes C₁-C₆-Alkyl darstellt, Z R₂CH(COOH)NH- oder R₁SCH₂- ist, R₁ Wasserstoff oder R₈CO-darstellt, R₈ C₁-C₁₀-Alkyl oder Phenyl bedeutet und R₂ C₁-C₁₀-Alkyl oder C₇-C₁₂-Phenylalkyl ist, und pharmazeutisch annehmbare Salze, Ester und Amide hievon.

- 2. Verbindung nach Anspruch 1, worin Z R₂CH(COOH)NH- und R₃ C₁-C₁₀-Alkyl oder C₃-C₁₀-Cycloalkyl bedeutet.
- 10 3. Verbindung nach Anspruch 2, worin Z R₂CH(COOH)NH- ist, R Methyl oder Aminobutyl bedeutet, R₂ n-Propyl oder Phenyläthyl darstellt, R₃ tert.Butyl ist und alle asymmetrischen Kohlenstoffatome in S-Konfiguration vorliegen.
- 15 4. 5-tert.Butyl-3-[N-(1-(S)-äthoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazol-2-(S)-carbonsäure,
5-tert.Butyl-3-[N²-(1-(S)-carboxy-3-phenylpropyl)-L-lysyl]-2,3-dihydro-1,3,4-thiadiazol-2-(S)-carbonsäure und
5-tert.Butyl-3-[N-(1-(S)-äthoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazol-2-(S)-carbonsäure
und pharmazeutisch annehmbare Salze hievon.
- 20 5. 3-[N-(1-(S)-Äthoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazol-2-(S)-carbonsäure,
Benzyl-3-[N-(1-(S)-äthoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazol-2-(R)-carboxylat,
Benzyl-3-[N-(1-(S)-äthoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-5-phenyl-1,3,4-thiadiazol-2-(S)-carboxylat,
2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-phenyl-1,3,4-thiadiazol-2-carbonsäure,
Äthyl-3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-phenyl-1,3,4-thiadiazol-2-carboxylat,
30 Benzyl-5-tert.butyl-3-[N-(1-(S)-äthoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazol-2-(R)-carboxylat,
Benzyl-5-tert.butyl-3-[H-(1-(S)-äthoxycarbonyl-3-phenylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazol-2-(S)-carboxylat,
Benzyl-3-[N⁶-benzyloxycarbonyl-N²-(1-(S)-benzyloxycarbonyl-3-phenylpropyl)-L-lysyl]-5-tert.butyl-
35 2,3-dihydro-1,3,4-thiadiazol-2-(R)-carboxylat,
Benzyl-3-[N⁶-benzyloxycarbonyl-N²-(1-(S)-benzyloxycarbonyl-3-phenylpropyl)-L-lysyl]-5-tert.butyl-
2,3-dihydro-1,3,4-thiadiazol-2-(2)-carboxylat,
Benzyl-5-tert.butyl-3-[N-(1-(S)-äthoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazol-2-(R)-carboxylat,
40 Benzyl-5-tert.butyl-3-[N-(1-(S)-äthoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazol-2-(S)-carboxylat,
2,3-Dihydro-3-(3-mercaptop-2-(S)-methyl-1-oxopropyl)-5-phenyl-1,3,4-thiadiazol-2-(S)-carbonsäure,
Benzyl-3-(3-acetylthio-2-(S)-methyl-1-oxopropyl)-2,3-dihydro-5-phenyl-1,3,4-thiadiazol-2-carboxylat,
2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-[4-(trifluormethyl)-phenyl]-1,3,4-thiadiazol-2-carbonsäure,
45 Benzyl-3-[3-acetylthio-1-oxopropyl]-2,3-dihydro-5-[4-(trifluormethyl)-phenyl]-1,3,4-thiadiazol-2-carboxylat,
5-tert.Butyl-3-[N-(1-(S)-äthoxycarbonylbutyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazol-2-(R)-carbonsäure,
5-tert.Butyl-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazol-2-carbonsäure,
50 2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-carbonsäure,
2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-(2-methylphenyl)-1,3,4-thiadiazol-2-carbonsäure,
5-(Furan-2-yl)-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazol-2-carbonsäure,
Äthyl-3-(3-acetylthio-1-oxopropyl)-2,3-dihydro-5-(naphthalin-2-yl)-1,3,4-thiadiazol-2-carboxylat,
5-(Adamant-1-yl)-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazol-2-carbonsäure,
55 Äthyl-5-(adamant-1-yl)-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazol-2-carboxylat,
2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-methyl-1,3,4-thiadiazol-2-carbonsäure,
5-Cyclohexyl-2,3-dihydro-3-(3-mercaptop-1-oxopropyl)-1,3,4-thiadiazol-2-carbonsäure,
2,3-Dihydro-3-(3-mercaptop-1-oxopropyl)-5-methylthio-1,3,4-thiadiazol-2-carbonsäure,

und pharmazeutisch annehmbare Salze hievon.

6. Verwendung einer Verbindung der Formel (I), wie in Anspruch 1 definiert, bei der Herstellung einer pharmazeutischen Formulierung zur Behandlung eines hypertonischen Zustandes.
- 5 7. Verfahren zur Herstellung einer Verbindung der Formel (I), wie in Anspruch 1 definiert, oder eines pharmazeutisch annehmbaren Salzes, Esters oder Amids hievon, umfassend
- 10 a) Entfernen einer Schutzgruppe von einer Verbindung der Formel (I), worin eine oder mehrere der Amino- oder Carbonsäuregruppen geschützt sind, oder
- b) Umsetzen einer Verbindung der Formel (II),




oder eines Salzes, Esters, Amids, Tautomers oder geschützten Derivates hievon, worin R₃ wie in Anspruch 1 definiert ist, mit einer Verbindung der Formel (III)

- 25 ZCHR₃OX (III),
- worin Z und R wie in Anspruch 1 definiert sind und X eine gute Abgangsgruppe ist,
- 30 c) Überführen einer Verbindung der Formel (I), wie in Anspruch 1 definiert, worin das asymmetrische Kohlenstoffatom des Thiadiazolringes in R-Konfiguration vorliegt, in eine entsprechende Verbindung, worin dieses Kohlenstoffatom in S-Konfiguration vorliegt,
- d) Umsetzen einer Verbindung der Formel (II), worin R₃, Y und n wie in Anspruch 1 definiert sind, mit einer Verbindung der Formel (VI)

ZCHR₃COOH (VI),

- 35 worin Z und R wie in Anspruch 1 definiert sind,
- e) Herstellen eines pharmazeutisch annehmbaren Salzes einer Verbindung der Formel (I), wie in Anspruch 1 definiert, durch Behandeln einer Verbindung der Formel (I), wie in Anspruch 1 definiert, oder eines weiteren Salzes, Esters, oder Amids hievon, mit einer Verbindung, die ein zur Verfügung stehendes, pharmazeutisch annehmbares Ion enthält und dazu in der Lage ist, die Verbindung der Formel (I) oder das andere Salz, den Ester oder das Amid hievon in ein pharmazeutisch annehmbares Salz der Verbindung der Formel (I) zu überführen, und gegebenenfalls Entschützen der erhaltenen Verbindung oder Überführen einer Verbindung der Formel (I) in ein pharmazeutisch annehmbares Salz, einen Ester oder ein Amid hievon oder vice versa.

- 45 8. Verbindung der Formel (II),



worin R₃ Wasserstoff, C₁-C₁₀-Alkyl, C₃-C₁₀-Cycloalkyl, SR₁₀, Furanyl, Phenyl oder C₇-C₁₂-Phenylalkyl oder Naphthalinyl bedeutet, wobei die Phenylgruppe gegebenenfalls durch C₁-C₈-Alkyl oder C₁-C₆-

EP 0 217 519 B1

Alkoxy substituiert ist, R₁₀ C₁-C₁₀-Alkyl darstellt, und Salze, Ester, Amide und Tautomere hieron.

9. Verbindung nach Anspruch 1 zur Verwendung als Heilmittel.
- 5 10. Pharmazeutische Formulierung umfassend eine Verbindung nach Anspruch 1 gemischt mit einem pharmazeutisch annehmbaren Verdünnungsmittel, Exzipienten oder Träger.

10

15

20

25

30

35

40

45

50

55